January 10, 2018 09:57 AM ESTUpdated May 26, 08:50 PM
Cell/Gene Tx

Blue­bird hopes for 3 drug ap­provals by 2019, in­clud­ing CAR-T and gene ther­a­pies

Brittany Meiling

Blue­bird bio is hop­ing for an FDA OK for three of its ex­per­i­men­tal drugs by 2019, in­clud­ing the CAR-T bb2121 part­nered with Cel­gene hat caused …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times